Loading company…
META Pharmaceuticals develops small-molecule drugs targeting immunometabolism.
META Pharmaceuticals develops inhibitors for autoimmune and metabolic diseases. Its pipeline includes candidates for conditions such as multiple sclerosis, lupus and rheumatoid arthritis. Founded in 2021, the company is based in Shenzhen, China. It raised series A funding led by XtalPi Inc. in February 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in